C. Lieftink

A fluorescence-based sensor screen identifies MED12 as a potential microsatellite instability regulator in colon cancer

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator

This study uses a CRISPR screen to identify genes critical for macrophage-mediated killing of prostate cancer cells, revealing AR as an immunomodulator that promotes resistance to macrophage attack.

Paradoxical activation of oncogenic signaling as a cancer treatment strategy

This study shows that inhibiting PP2A and WEE1 together can kill colon cancer cells by causing DNA replication collapse and cell death, and that resistance to this treatment suppresses tumor growth.

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

This study identifies genetic and compound factors that modulate cancer cell response to the drug indisulam, revealing therapeutic strategies for its clinical reuse.

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity

The paper identifies that combining indisulam with palbociclib enhances senescence in cancer cells by inhibiting CDK2 kinase activity.

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps

This study identifies loss of LIG3 as a factor that reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by increasing ssDNA gaps.

Glucocorticoids regulate cancer cell dormancy

This study identifies the mechanism by which glucocorticoid receptor activation induces cancer cell dormancy through CDKN1C and FOXO1/IRS2 signaling, with implications for cancer therapy.